Form 4: Ultragenyx CEO Emil Kakkis Sells 20,000 Shares of Common Stock

Ultragenyx Pharmaceutical Inc.'s CEO, Emil D. Kakkis, recently sold 20,000 shares of common stock at an average price of $55.85.

Summary

• On September 3, 2024, Emil D. Kakkis, the President & CEO and a Director of Ultragenyx Pharmaceutical Inc., sold 20,000 shares of common stock.
• The sale was executed at a weighted average price of $55.85 per share, with individual transactions ranging from $55.02 to $57.55.
• Following the transaction, Kakkis directly owns 564,597 shares and indirectly owns 2,223,985 shares through the Emil Kakkis and Jenny Soriano Living Trust.
• The reported holdings include shares underlying Restricted Stock Units (RSUs) that are subject to vesting conditions.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it simply reports a transaction. Insider sales can sometimes be viewed negatively, but without additional context, it's difficult to assess the overall impact.

Industry Context

Insider selling can sometimes be interpreted negatively by the market, as it may suggest a lack of confidence in the company's future prospects. However, it's also common for executives to sell shares for personal financial planning reasons.

Stakeholder Impact

• The stock sale could potentially influence shareholder sentiment, depending on how the market interprets the transaction.

Key Dates